For FGFR4 rs1966265 polymorphism, the findings revealed that this variant significantly reduced the risk of cancer susceptibility in recessive (OR = 0.87, 95% CI = 0.78–0.97, P=0.009, TT vs CT+CC) model (Table 2 and Figure 3). This evidence concerns the gene FGFR4 and cancer.